LDL-Cholesterol Lowering Effect of KB2115 as Add on to Ezetimibe
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
Eprotirome (KB2115) is a liver selective thyroid hormone that can induce hyperthyroidism in
the liver, while an euthyroid state is preserved in the extrahepatic tissue. Eprotirome has
in clinical trials demonstrated pronounced reduction of several independent risk factors for
the development of atherosclerotic cardiovascular diseases.
The purpose of the study is to assess the efficacy and safety of KB2115 as add on therapy to
ezetimibe following 10 weeks of exposure compared to placebo. The aim of the study is to
assess efficacy (LDL-cholesterol lowering effects) and safety of KB2115 and to define a
clinically relevant dose or dose range for future studies.